Interview with Jenny Winter, Managing Director, AstraZeneca Hungary
The Hungarian pharmaceutical environment has been undergoing many changes recently, such as a sales tax increase to 20%. Do you feel this is a climate of threat to MNCs in…
Address: 1113 Budapest, Bocskai út 134-146. Hungary,Hungary
Tel: +36 1 883 6500
Web: http://www.astrazeneca.hu/
We are active in over 100 countries with a growing presence in emerging markets including China, Brazil, Mexico and Russia.
We employ over 61,000 people (46% in Europe, 24% in the North America, 7% in Latin America and 24% in Asia, Africa and Australasia).
We invest over $4 billion in R&D each year. Around 15,7001 people work in our R&D organisation and we have 14 major R&D centres in eight countries, including Sweden, the US and the UK.
We have 9,300 employees at 23 supply and manufacturing sites in 16 countries.
In 2010, our worldwide sales totalled over $33 billion (including 10 medicines with sales of over $1 billion each).
Alongside our commitment to competitiveness and performance, we continue to be led by our core values to deliver business success responsibly. We are positioned in the top 8% in the sector in the Dow Jones World and STOXX (European) Sustainability Indexes.
We focus our skills and resources on six important areas of healthcare, which include some of the world’s most serious illnesses:
– Cardiovascular
– Gastrointestinal
– Infection
– Neuroscience
– Oncology
– Respiratory
The Hungarian pharmaceutical environment has been undergoing many changes recently, such as a sales tax increase to 20%. Do you feel this is a climate of threat to MNCs in…
Providing universal health coverage to the nation’s roughly 10 million citizens, Hungary’s National Health Insurance Fund (OEP) has one of the most comprehensive and complex structures in Europe. The organization’s…
Chronic underfinancing is a common pitfall for many former socialist states and Hungary is no exception. Total health spending ultimately accounted for 8.0 percent of GDP in Hungary in 2014, which…
Mylan Hungary’s Tamas Uri discusses transitioning into both a branded and generic business dedicated company, Mylan’s expansion in Hungary, and how the pharmaceutical industry can be a key player in improving the…
Hungary’s Minister of Foreign Affairs and Trade Péter Szijjártó highlights the significant role that foreign direct investments have played in developing the country’s healthcare and life science sector, while detailing…
György Bodoky, Head of the Oncology Department at Unified Szent István and Szent László Hospital, shares his insights on the state of oncological care in Hungary, the current effects of…
János Burovincz, Managing Director of Patent, shares his insights on building a company from scratch, the importance of maintaining a diverse portfolio that can quickly adapt to market needs as…
GSK Hungary’s Claire Roger discusses the value of ethical promotion both in improving transparency and benefiting all stakeholders. She further describes the strategic role and economic impact of GSK’s vaccine plant in…
Róbert Ésik, President of the Hungarian Investment Promotion Agency (HIPA), shares his insights into what makes Hungary such an attractive destination for foreign direct investment and ways that the agency…
To effectively reform old habits requires diligence, consistency and, above all, patience. As an introduction for our readers, could you describe the initial objectives that you set for yourself…
Veronika Ferencz, Sales and Marketing Director for Exeltis Hungary, discusses the evolving and expanding footprint of the company in Hungary, the challenges strict regulations on food supplements are causing, as…
The leadership of Meditop discuss their history as the first non-privatized, private Hungarian pharmaceutical company, their ongoing strategies for growth in the country, and their evolving portfolio abroad. They also…
The recently appointed CEO of Servier Hungary, Dr. Jan Frederic Kesselhut highlights his initial perceptions of the Hungarian pharmaceutical market and depicts the significant role that the Servier Research Institute…
See our Cookie Privacy Policy Here